Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

4.32USD
3:59pm EST
Change (% chg)

$-0.25 (-5.47%)
Prev Close
$4.57
Open
$4.88
Day's High
$4.90
Day's Low
$4.23
Volume
599,625
Avg. Vol
271,627
52-wk High
$7.88
52-wk Low
$4.04

Chart for

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $648.77
Shares Outstanding(Mil.): 141.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Ziopharm Oncology reports third quarter financial results

* Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities

Nov 06 2017

BRIEF-Ziopharm Oncology reports Q2 loss per share $0.13

* Ziopharm Oncology reports second quarter 2017 financial results and provides update on recent activities

Jul 31 2017

BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

* Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

Jun 28 2017

BRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology

* CVI Investments Inc reports a 6.8 percent passive stake in Ziopharm Oncology Inc as of May 11, 2017 - sec filing Source text - http://bit.ly/2q42eo3 Further company coverage:

May 22 2017

Earnings vs. Estimates